Reviewing Vincerx Pharma (NASDAQ:VINC) & Trevena (NASDAQ:TRVN)

Risk and Volatility

Trevena has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Vincerx Pharma has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500.

Valuation and Earnings

This table compares Trevena and Vincerx Pharma”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevena	$443,000.00	0.03	-$40.29 million	($47.04)	0.00
Vincerx Pharma	N/A	N/A	-$40.16 million	($5.31)	0.00

Vincerx Pharma has lower revenue, but higher earnings than Trevena. Vincerx Pharma is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

13.6% of Trevena shares are held by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are held by institutional investors. 2.7% of Trevena shares are held by insiders. Comparatively, 15.6% of Vincerx Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Trevena and Vincerx Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Trevena	N/A	N/A	-119.55%
Vincerx Pharma	N/A	-248.33%	-132.73%

Summary

Vincerx Pharma beats Trevena on 5 of the 9 factors compared between the two stocks.

About Trevena

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

About Vincerx Pharma

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.